Zacks Research Issues Pessimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Investment analysts at Zacks Research cut their Q2 2026 earnings per share estimates for Teva Pharmaceutical Industries in a research note issued on Monday, April 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.60 for the quarter, down from their previous estimate of $0.62. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q3 2026 earnings at $0.78 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.56 EPS, Q1 2027 earnings at $0.60 EPS and FY2027 earnings at $2.77 EPS.

Several other equities analysts have also weighed in on TEVA. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Up 3.8 %

TEVA stock opened at $16.22 on Thursday. The firm’s fifty day moving average is $15.11 and its 200 day moving average is $17.49. The firm has a market cap of $18.39 billion, a PE ratio of -11.19, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Diversify Advisory Services LLC grew its holdings in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after buying an additional 496 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after purchasing an additional 699 shares during the last quarter. Bfsg LLC grew its stake in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company’s stock valued at $168,000 after buying an additional 790 shares during the period. Townsquare Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock worth $885,000 after buying an additional 812 shares during the last quarter. Finally, Metis Global Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after buying an additional 860 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.